☰

Hongyun Zhao - Publications

Affiliations: 
2016 Chemical Engineering Rice University, Houston, TX 
 2016- Harvard Medical School, Boston, MA, United States 
Tree Info Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 He LN, Li H, Du W, Fu S, Luo L, Chen T, Zhang X, Chen C, Jiang Y, Wang Y, Wang Y, Yu H, Zhou Y, Lin Z, Zhao Y, ... ... Zhao H, et al. Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy. Iscience. 26: 107058. PMID 37416452 DOI: 10.1016/j.isci.2023.107058  0.321
2022 Zhao H, Teng D, Yang L, Xu X, Chen J, Jiang T, Feng AY, Zhang Y, Frederick DT, Gu L, Cai L, Asara JM, Pasca di Magliano M, Boland GM, Flaherty KT, et al. Myeloid-derived itaconate suppresses cytotoxic CD8 T cells and promotes tumour growth. Nature Metabolism. PMID 36376563 DOI: 10.1038/s42255-022-00676-9  0.476
2022 Guan S, Chen X, Chen Y, Xie W, Liang H, Zhu X, Yang Y, Fang W, Huang Y, Zhao H, Zhuang W, Liu S, Huang M, Wang X, Zhang L. FOXM1 variant contributes to gefitinib resistance via activating wnt/β-catenin signal pathway in non-small cell lung cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35695863 DOI: 10.1158/1078-0432.CCR-22-0791  0.308
2021 Zhao H, Luo F, Xue J, Li S, Xu RH. Emerging immunological strategies: recent advances and future directions. Frontiers of Medicine. PMID 34874513 DOI: 10.1007/s11684-021-0886-x  0.302
2021 Luo F, Zeng KM, Cao JX, Zhou T, Lin SX, Ma WJ, Yang YP, Zhang ZH, Lu FT, Huang Y, Zhao HY, Zhang L. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study. Lipids in Health and Disease. 20: 109. PMID 34544437 DOI: 10.1186/s12944-021-01538-1  0.33
2021 Zhu Z, Parikh P, Zhao H, Givens NT, Beck DB, Willson CM, Bai Q, Wakefield MR, Fang Y. Targeting immunometabolism of neoplasms by interleukins: A promising immunotherapeutic strategy for cancer treatment. Cancer Letters. PMID 34153401 DOI: 10.1016/j.canlet.2021.06.013  0.456
2021 Zhao H, Swanson KD, Zheng B. Therapeutic Repurposing of Biguanides in Cancer. Trends in Cancer. PMID 33865798 DOI: 10.1016/j.trecan.2021.03.001  0.462
2020 Zhou T, Zhang L, Liu T, Yang Y, Luo F, Zhang Z, Huang Y, Zhao H, Zhang L, Zhao Y. Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. Annals of Translational Medicine. 8: 1589. PMID 33437788 DOI: 10.21037/atm-20-2305  0.469
2020 Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, Co NN, Rynne-Vidal A, Schmandt R, Anderson ML, Lu KH, et al. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nature Communications. 11: 3546. PMID 32669559 DOI: 10.1038/S41467-020-17383-2  0.775
2020 Ma Y, Fang W, Zhang Y, Yang Y, Hong S, Zhao Y, Xie S, Ge J, Zhou H, Zhao H, Zhang L. KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small-Cell Lung Cancer. The Oncologist. PMID 32134163 DOI: 10.1634/theoncologist.2020-0067  0.307
2020 Zheng Q, Hong S, Huang Y, Zhao H, Yang Y, Hou X, Zhao Y, Ma Y, Zhou T, Zhang Y, Fang W, Zhang L. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients. Clinical and Translational Medicine. 9: 17. PMID 32067121 DOI: 10.1186/s40169-020-0269-y  0.304
2020 Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Hong S, Chen G, Zhao S, Chen X, Zhang Z, Xian W, Shen J, Huang Y, Zhao H, Zhang L. Impact of prior cancer history on the overall survival of younger patients with lung cancer. Esmo Open. 5. PMID 32054633 DOI: 10.1136/esmoopen-2019-000608  0.37
2019 Ma Y, Xin S, Lin Q, Zhuang W, Zhao Y, Zhu X, Zhao H, Huang M, Xun X, Yang Y, Fang W, Zhang L, Wang X. The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Annals of Translational Medicine. 7: 806. PMID 32042822 DOI: 10.21037/atm.2019.12.60  0.344
2019 Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel B, Kang C, Choudhary G, Gordon-Mitchell S, Aluri S, Bhattacharyya S, Sahu S, et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife. 8. PMID 31663852 DOI: 10.7554/Elife.50663  0.742
2019 Zhou H, Zhang Y, Liu J, Fang W, Yang Y, Hong S, Chen G, Zhao S, Shen J, Xian W, Zhang Z, Chen X, Zhao H, Huang Y, Zhang L. Impact of prior cancer on outcomes in nasopharyngeal carcinoma. Annals of Translational Medicine. 7: 299. PMID 31475169 DOI: 10.21037/atm.2019.05.78  0.353
2019 Luo F, Zhang Z, Liao K, Zhang Y, Ma Y, Hu Z, Zeng K, Huang Y, Zhang L, Zhao H. Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. Annals of Translational Medicine. 7: 253. PMID 31355220 DOI: 10.21037/atm.2019.04.65  0.356
2019 Zhao H, Zheng B. Dual Targeting of Autophagy and MEK in KRAS Mutant Cancer. Trends in Cancer. 5: 327-329. PMID 31208693 DOI: 10.1016/J.Trecan.2019.04.003  0.447
2019 Fang W, Ma Y, Yin JC, Hong S, Zhou H, Wang A, Wang F, Bao H, Wu X, Yang Y, Huang Y, Zhao H, Shao YW, Zhang L. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31085721 DOI: 10.1158/1078-0432.CCR-19-0585  0.301
2018 Zhou H, Huang Y, Qiu Z, Zhao H, Fang W, Yang Y, Zhao Y, Hou X, Ma Y, Hong S, Zhou T, Zhang Y, Zhang L. Impact of Prior Cancer History on the Overall Survival of Patients Newly Diagnosed with Cancer: A Pan-cancer Analysis of the SEER Database. International Journal of Cancer. PMID 29667174 DOI: 10.1002/ijc.31543  0.435
2018 Wu M, Zhao H, Guo L, Wang Y, Song J, Zhao X, Li C, Hao L, Wang D, Tang J. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer. Drug Delivery. 25: 226-240. PMID 29313393 DOI: 10.1080/10717544.2017.1422300  0.317
2017 Zhao H, Achreja A, Iessi E, Logozzi M, Mizzoni D, Di Raimo R, Nagrath D, Fais S. The key role of extracellular vesicles in the metastatic process. Biochimica Et Biophysica Acta. 1869: 64-77. PMID 29175553 DOI: 10.1016/J.Bbcan.2017.11.005  0.699
2017 Achreja A, Zhao H, Yang L, Yun TH, Marini J, Nagrath D. Exo-MFA - A 13C metabolic flux analysis to dissect tumor microenvironment-secreted exosome contributions towards cancer cell metabolism. Metabolic Engineering. PMID 28087332 DOI: 10.1016/J.Ymben.2017.01.001  0.802
2017 Yeung CLA, Achreja A, Zhao H, Yeung T, Schmandt R, Yip DK, Lu KH, Nagrath D, Mok SC. Abstract 5911: Omentin drives metabolic shift in ovarian cancer cells in the omental tumor microenvironment Cancer Research. 77: 5911-5911. DOI: 10.1158/1538-7445.Am2017-5911  0.782
2017 Achreja A, Zhao H, Zhu Z, Gerszberg J, Konopleva MY, Andreeff M, Nagrath D. Abstract 439: Metabolic flux analysis reveals targets to sensitize chemoresistance in acute myeloid leukemia induced by mesenchymal stromal cell-derived exosomes Cancer Research. 77: 439-439. DOI: 10.1158/1538-7445.Am2017-439  0.681
2017 Zhao H, Achreja A, Zhu Z, Rawi AN, Konopleva M, Andreeff M, Nagrath D. Abstract 4323: Metabolic reprogramming in acute myeloid leukemia cells by mesenchymal stromal cell-derived exosomes induces chemoresistance Cancer Research. 77: 4323-4323. DOI: 10.1158/1538-7445.Am2017-4323  0.743
2016 Chen Z, Chen Y, Xu M, Chen LK, Zhang X, To KK, Zhao H, Wang F, Xia Z, Chen X, Fu L. Osimertinib (AZD9291) enhanced the efficacy of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro, in vivo and ex vivo. Molecular Cancer Therapeutics. PMID 27196753 DOI: 10.1158/1535-7163.MCT-15-0939  0.319
2016 Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L. Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Scientific Reports. 6: 23850. PMID 27072409 DOI: 10.1038/srep23850  0.391
2016 Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini J, Tudawe T, Seviour EG, San Lucas FA, Alvarez H, Gupta S, Maiti SN, Cooper L, Peehl D, et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife. 5. PMID 26920219 DOI: 10.7554/Elife.10250  0.811
2015 He X, Zhou T, Yang Y, Hong S, Zhan J, Hu Z, Fang W, Qin T, Ma Y, Zhao Y, Cheng Z, Huang Y, Zhao H, Yang G, Zhang L. Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 25922292 DOI: 10.1016/j.cllc.2015.03.005  0.321
2015 Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini JC, Tudawe T, Seviour EG, Lucas FAS, Alvarez H, Gupta S, Maiti SN, Cooper L, Peehl D, et al. Author response: Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism Elife. DOI: 10.7554/Elife.10250.022  0.787
2014 Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Design, Development and Therapy. 8: 1827-37. PMID 25336925 DOI: 10.2147/DDDT.S67961  0.347
2014 Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology. 10: 728. PMID 24799285 DOI: 10.1002/Msb.20134892  0.79
2014 Zhao H, Yang L, Achreja A, Marini J, Peehl D, Nagrath D. Abstract 3594: Tumor microenvironment derived exosomes regulate prostate cancer metabolism Cancer Research. 74: 3594-3594. DOI: 10.1158/1538-7445.Am2014-3594  0.792
2014 Achreja A, Yang L, Zhao H, Marini J, Nagrath D. Abstract 3372: Constraints-based metabolic flux analysis approach links tumor stage to metabolic adaptations and survival in cancer cells Cancer Research. 74: 3372-3372. DOI: 10.1158/1538-7445.Am2014-3372  0.795
2013 Yang L, Zhao H, Marini JC, Jeter C, Tang D, Nagrath D. Abstract 5413: Role of NANOG in modulating cancer cell metabolism. Cancer Research. 73: 5413-5413. DOI: 10.1158/1538-7445.Am2013-5413  0.817
2013 Achreja A, Yang L, Zhao H, Marini JC, Nagrath D. Abstract 1892: Integrated energetics and flux analysis reveals differential metabolic reprogramming in highly and less invasive cancer cells. Cancer Research. 73: 1892-1892. DOI: 10.1158/1538-7445.Am2013-1892  0.784
2012 Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F, Zhao HY. Prognostic significance of TAZ expression in resected non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 799-807. PMID 22481233 DOI: 10.1097/JTO.0b013e318248240b  0.339
2010 Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KK, Ambudkar SV, Chen ZS, Fu LW. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Research. 70: 7981-91. PMID 20876799 DOI: 10.1158/0008-5472.CAN-10-0111  0.34
Show low-probability matches.